TRPM2 (transient receptor potential melastatin 2) deletion can protect mice from CPZ-induced demyelination, synaptic loss, microglial activation, NLRP3 inflammasome activation, and pro-inflammatory cytokine production, ultimately ameliorating cognitive decline [157]. The gene discussed is TRPM2; the disease is Mental deterioration.